Langer lab spin­out Lyn­dra rais­es $60.5M in bid to re­place ex­ist­ing HIV, schiz­o­phre­nia, opi­oid abuse treat­ments

Two months af­ter un­veil­ing Phase II da­ta for their long-act­ing schiz­o­phre­nia pill, Lyn­dra Ther­a­peu­tics has raised a $60.5 mil­lion Se­ries C to push it through a piv­otal tri­al.

The new round, led by the VC arm of in­sur­ance gi­ant AIG, brings Lyn­dra’s to­tal fund­ing to over $160 mil­lion as they look to re­for­mu­late ex­ist­ing dai­ly pills in­to week­ly pills. It will be im­me­di­ate­ly used to fund a Phase III study for LYN-005, a week­ly form of the decades-old an­tipsy­chot­ic risperi­done.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER